Carboxymethyl kappa carrageenan polyelectrolyte multilayers as blood contacting surfaces.
Ontology highlight
ABSTRACT: This research introduces carboxymethyl kappa-carrageenan-chitosan polyelectrolyte multilayers as a promising and sustainable alternative to heparin, used in surface treatments for blood-contacting medical devices. The polysaccharide-based surface coatings have good cytocompatibility and resist microbial adhesion of both Pseudomonas aeruginosa and Staphylococcus aureus. The blood compatibility of surfaces containing carboxymethyl-kappa-carrageenan was directly compared to similar polyelectrolyte multilayers containing heparin. The carboxymethyl-kappa-carrageenan surfaces inhibit whole-blood clotting like heparin-containing surfaces. Blood clotting is mediated by both protein-surface and cell-surface interactions. The carboxymethyl-kappa-carrageenan surfaces adsorb more fibrinogen and less a
SUBMITTER: Madruga LYC
PROVIDER: S-EPMC12671015 | biostudies-literature | 2025
REPOSITORIES: biostudies-literature
ACCESS DATA